AstraZeneca: phase III results of THALES trial

(CercleFinance.com) - The results of the THALES Phase III trial have shown that AstraZeneca's Brilinta (ticagrelor) 90 mg, used twice daily and taken with aspirin for 30 days, achieved a statistically significant and clinically significant reduction in the main composite endpoint for stroke and death, compared to aspirin alone.


The THALES trial was conducted in over 11,000 patients who had suffered a minor acute ischemic stroke or high-risk transient ischemic attack (AIT) within 24 hours of starting treatment.

Brilinta is approved in over 110 countries for the treatment of acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events (CV) in high-risk patients who have suffered a heart attack.


Copyright (c) 2020 CercleFinance.com. All rights reserved.